ALX Oncology (ALXO) will highlight progress across its clinical pipeline, including continued advancement of investigational CD47-blocker evorpacept and planned entry into the clinic of its novel ...
ALX Oncology stock opened at $1.03 on Tuesday. The company has a debt-to-equity ratio of 0.07, a quick ratio of 4.82 and a current ratio of 4.82. ALX Oncology has a 52 week low of $0.96 and a 52 ...
ALX Oncology announced promising results from the ASPEN-06 Phase 2 clinical trial of its CD47-blocker, evorpacept, at the 2025 ASCO Gastrointestinal Cancers Symposium. This investigational ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback